six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (hba1c), fasting blood sugar, postprandial blood sugar, and weight of 22 indian obese patients with type 2 diabetes mellitus with no serious adverse events. therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese typ...

Six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (HbA1c), fasting blood sugar, postprandial blood sugar, and weight of 22 Indian obese patients with type 2 diabetes mellitus with no serious adverse events. Therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese typ...

Background: Diabetes mellitus (DM) is associated with a spectrum of cancers where the metabolic antecedents, consequences, and therapy might affect cancer risk. The association between hepatocellular carcinoma (HCC) DM had been confirmed. Approaches to HCC prevention focus on molecular regulators disease process defined as inflammation-fibrosis-cancer axis. AMP-activated protein kinase (AMPK) a...

Short-term and long-term effects of bromocriptine mesylate (10 mg/kg i.p.) on cyclic AMP contents of the liver and some endocrine glands have been investigated in the presence and absence of sulpiride (10 mg/kg i.p.). Results revealed that bromocriptine caused significant elevations in the cyclic AMP contents of the liver and reduction in its adrenocortical content. Bromocriptine effect on the ...

Problem statement: Our previous research has shown that mitochondrial ATPase may have a role in the action of dopaminergic D2 receptors. It is therefore, thought of interest to investigate the effect of bromocriptine, sulpiride or their combination on the mitochondrial and microsomal ouabain sensitive and ouabain insensitive Na/K-ATPase in the liver of rats. Approach: In vivo treatment was carr...

Fatigue is the most commonly reported and most disabling of all post-polio sequelae (PPS). Bromocriptine mesylate (Parlodel) was employed in a placebo-controlled trial in five survivors of paralytic polio who continued to report moderate to severe daily fatigue after complying with the conservative treatments prescribed for PPS. Placebo was given for 4 wk followed by increasing doses of bromocr...

Twenty five patients with hyperprolactinaemia were treated with pergolide mesylate, a new dopamine receptor agonist. Twenty three received treatment for six to 20 months, and in all serum prolactin concentrations were considerably reduced. In most patients prolactin concentrations were maintained in the normal range by a low, once daily dose of pergolide and reversal of associated reproductive ...

I n the article Gaziano et al, “Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects,” which published online October 12, 2012, and appeared in the October 2012 issue of the journal ( J Am Heart Assoc. 2012;1:e002279 doi: 10.1161/JAHA.112.002279), an error occurred in Table 3. In the row “CV death”,...

Bromocriptine mesylate quick release formulation has recently been approved by FDA for the treatment of diabetes mellitus. Till now it has been mainly known for its use in Parkinsonism and for suppression of lactation. Present study evaluates and compares the antihyperglycemic effect of the combination of bromocriptine and metformin with either of the two drugs taken alone. For this fasting blo...